During the last session, Keros Therapeutics Inc (NASDAQ:KROS)’s traded shares were 0.33 million, with the beta value of the company hitting 1.28. At the end of the trading day, the stock’s price was $52.28, reflecting an intraday loss of -3.17% or -$1.71. The 52-week high for the KROS share is $73.00, that puts it down -39.63 from that peak though still a striking 48.32% gain since the share price plummeted to a 52-week low of $27.02. The company’s market capitalization is $1.89B, and the average trade volume was 338.50K shares over the past three months.
Keros Therapeutics Inc (NASDAQ:KROS) trade information
Keros Therapeutics Inc (KROS) registered a -3.17% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.17% in intraday trading to $52.28, hitting a weekly high. The stock’s 5-day price performance is -3.67%, and it has moved by -11.31% in 30 days. Based on these gigs, the overall price performance for the year is 13.16%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Keros Therapeutics Inc (KROS) estimates and forecasts
Statistics show that Keros Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Keros Therapeutics Inc (KROS) shares have gone up 64.09% during the last six months, with a year-to-date growth rate less than the industry average at 4.23% against 14.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -111.11%. While earnings are projected to return 4.88% in 2024.
KROS Dividends
Keros Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
